ALYFTREK

Product Overview

About ALYFTREK

ALYFTREK is a prescription medication containing the active ingredients TEZACAFTOR, DEUTIVACAFTOR, and VANZACAFTOR (VANZACAFTOR CALCIUM). It is used to treat cystic fibrosis in patients aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one copy of the F508del mutation and one copy of the R117H mutation or one copy of the R334W mutation or one copy of the R347P mutation or one copy of the R352Q mutation or one copy of the R553X mutation or one copy of the R560T mutation or one copy of the R1162X mutation or one copy of the R1220X mutation or one copy of the 621+1G>T mutation or one copy of the 711+3A>T mutation or one copy of the 1898+4A>G mutation or one copy of the 2789+5G>A mutation or one copy of the 3272-26A>G mutation or one copy of the 3849+10kbC>T mutation or one copy of the 4055delC mutation or one copy of the 4060delC mutation or one copy of the 4153TT>CT mutation or one copy of the 4412delA mutation or one copy of the 4500delT mutation or one copy of the 4736+1G>T mutation or one copy of the 4750-12C>T mutation or one copy of the 4760-10kbC>T mutation or one copy of the 5072-2A>G mutation or one copy of the 5080insA mutation or one copy of the 621+1G>T mutation or one copy of the 711+3A>T mutation or one copy of the 1898+4A>G mutation or one copy of the 2789+5G>A mutation or one copy of the 3272-26A>G mutation or one copy of the 3849+10kbC>T mutation or one copy of the 4055delC mutation or one copy of the 4060delC mutation or one copy of the 4153TT>CT mutation or one copy of the 4412delA mutation or one copy of the 4500delT mutation or one copy of the 4736+1G>T mutation or one copy of the 4750-12C>T mutation or one copy of the 4760-10kbC>T mutation or one copy of the 5072-2A>G mutation or one copy of the 5080insA mutation.

Key Benefits & Uses

• Treatment of cystic fibrosis in patients aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the specified mutations.
• Improvement in lung function and reduction in sweat chloride levels.
• Enhanced quality of life for patients with cystic fibrosis.

Active Ingredient & Action

TEZACAFTOR, DEUTIVACAFTOR, and VANZACAFTOR (VANZACAFTOR CALCIUM) work by targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for